Literature DB >> 25901557

Computed tomography screening: the international early lung cancer action program experience.

Claudia I Henschke1, Paolo Boffetta2, David F Yankelevitz1, Nasser Altorki3.   

Abstract

The International Early Lung Cancer Action Program (I-ELCAP) used a novel study design that provided quantitative information about annual CT screening for lung cancer. The results stimulated additional studies of lung cancer screening and ultimately led to the National Lung Screening Trial (NLST) being initiated in 2002, as the initial report in 1999 was sufficiently compelling to reawaken interest in screening for lung cancer. The authors think that the I-ELCAP and NLST "story" provides a strong argument for relevant agencies to consider alternative study designs for the public funding of studies aimed at evaluating the effectiveness of screening and other medical trials.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Assessment of benefit; CT screening; Curability; Cure rate; Diagnostic performance; Lung cancer; Screening study design

Mesh:

Year:  2015        PMID: 25901557     DOI: 10.1016/j.thorsurg.2014.12.001

Source DB:  PubMed          Journal:  Thorac Surg Clin            Impact factor:   1.750


  3 in total

Review 1.  Impact of low-dose computed tomography (LDCT) screening on lung cancer-related mortality.

Authors:  Asha Bonney; Reem Malouf; Corynne Marchal; David Manners; Kwun M Fong; Henry M Marshall; Louis B Irving; Renée Manser
Journal:  Cochrane Database Syst Rev       Date:  2022-08-03

Review 2.  The importance of the regimen of screening in maximizing the benefit and minimizing the harms.

Authors:  Claudia I Henschke; Kunwei Li; Rowena Yip; Mary Salvatore; David F Yankelevitz
Journal:  Ann Transl Med       Date:  2016-04

3.  The Regimen of Computed Tomography Screening for Lung Cancer: Lessons Learned Over 25 Years From the International Early Lung Cancer Action Program.

Authors:  Claudia I Henschke; Rowena Yip; Dorith Shaham; Javier J Zulueta; Samuel M Aguayo; Anthony P Reeves; Artit Jirapatnakul; Ricardo Avila; Drew Moghanaki; David F Yankelevitz
Journal:  J Thorac Imaging       Date:  2021-01       Impact factor: 5.528

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.